Primary Outcomes from a Randomized, Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)

Beneficial Effect of Belatacept on Health-Related Quality of Life and Perceived Side Effects: Results From the BENEFIT and BENEFIT-EXT Trials.

Dobbels, Fabienne
Wong, S
Min, Y
Sam, J
Kalsekar, A

January 2014

BACKGROUND: Patient-reported outcomes are increasingly incorporated in drug evaluation trials. Wheth...

Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT

Florman, Sander
Vincenti, Flavio
Durrbach, Antoine
Abouljoud, Marwan S
Bresnahan, Barbara
Garcia, Valter D
Mulloy, Laura
Rice, Kim
Rostaing, Lionel
Zayas, Carlos
Calderon, Kellie
Meier-Kriesche, Ulf
Polinsky, Martin
Yang, Lingfeng
Medina Pestana, Jose
Larsen, Christian P

April 2018

Clinical outcomes are generally worse for black vs nonblack renal allograft recipients. In BENEFIT a...

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial

Grinyó, Josep M.
del Carmen Rial, Maria
Alberu, Josefina
Steinberg, Steven M.
Manfro, Roberto C.
Nainan, Georgy
Vincenti, Flavio
Jones-Burton, Charlotte
Kamar, Nassim

November 2016

BackgroundIn a phase 2 study, kidney transplant recipients of low immunologic risk who switched from...

Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)

Vincenti, Flavio
Grinyo, Josep M.
Charpentier, Bernard
Pestana, Jose Osmar Medina
Rostaing, Lionel
Vanrenterghem, Yves
Di Russo, Gregory B.
Garg, Pushkal
Lin, Chen-Sheng
Larsen, Christian

August 2009

Univ Calif San Francisco, Transplant Ctr, San Francisco, CA 94143 USAUniv Hosp Bellvitge, Div Nephro...

Outcomes as a Function of Donor Criteria from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT-EXT).

Florman, Sander
Durrbach, Antoine
Larsen, Christian
Pestana, Jose Osmar Medina
Vanrenterghem, Yves
Vincenti, Flavio
Block, Alan
Garg, Pushkal
Copley, J. Brian
Xing, Jun
Grinyo, Josep

April 2010

Mt Sinai Med Ctr, New York, NY USAEmory Univ, Atlanta, GA 30322 USAUnifesp, Hosp Rim & Hipertens, Sa...

A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)

Durrbach, A.
Pestana, Jose Osmar Medina
Pearson, T.
Vincenti, F.
Garcia, V. D.
Campistol, J.
del Carmen Rial, M.
Florman, S.
Block, A.
Di Russo, G.
Xing, J.
Garg, P.
Grinyo, J.

March 2010

Recipients of extended criteria donor (ECD) kidneys are at increased risk for graft dysfunction/loss...

Long-Term Outcomes in Belatacept-Treated vs. Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results from BENEFIT-EXT, a Phase III Randomized Study

Durrbach, A
Pestana, J M
Florman, S
Del Carmen Rial, M
Rostaing, L
Kuypers, Dirk
Matas, A
Wekerle, T
Polinsky, M
Meier-Kriesche, H U
Munier, S
Grinyó, J

November 2016

In BENEFIT-EXT (NCT00114777), extended criteria donor kidney recipients were randomized to receive b...

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

Larsen, Christian P.
Grinyo, Josep
Medina-Pestana, Jose
Vanrenterghem, Yves
Vincenti, Flavio
Breshahan, Barbara
Campistol, Josep M.
Florman, Sander
del Carmen Rial, Maria
Kamar, Nassim
Block, Alan
Di Russo, Gregory
Lin, Chen-Sheng
Garg, Pushkal
Charpentier, Bernard

December 2010

Background. At 1 year, belatacept was associated with similar patient/graft survival, better renal f...

Belatacept and long-term outcomes in kidney transplantation

Vincenti, Flavio
Rostaing, Lionel
Grinyó Boira, Josep M.
Rice, Kim
Steinberg, Steven
Gaite, Luis
Moal, Marie-Christine
Mondragon-Ramírez, Guillermo A.
Kothari, Jatin
Polinsky, Martin S.
Meier-Kriesche, Herwig-Ulf
Munier, Stephane
Larsen, Christian P.

June 2021

Background: in previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosuppression, as...

G. Mondragon-Ramirezj, R. Reyes-Acevedok,

K. Ricel
L. Rostaingm
S. Steinbergn
J. Xingo
M. Agarwalo
M. B. Harlero
B. Charpentierp
Ehospital Dom Vicente Scherer–complexo Hospitalar
Khospital Miguel Hidalgo De Aguascalientes

October 2015

*Drs. Vincenti and Larsen contributed equally to the work described. The clinical profile of belatac...

and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2011.03914.x Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

J. O. Medina Pestanaa
J. M. Grinyob
Y. Vanrenterghemc
T. Beckerd
J. M. Campistole
S. Flormanf
V. D. Garciag
N. Kamarh
P. Langi
R. C. Manfroj
P. Massarik
M. D. C. Riall
M. A. Schnitzlerm
S. Vitkon
T. Duano
A. Blockp
M. B. Harlerp
A. Durrbachq
Medizinische Hochschule Hannover Hannover

October 2015

Recipients of extended-criteria donor (ECD) kid-neys have poorer long-term outcomes compared t

3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies

Charpentier, Bernard
Grinyo, Josep
Pestana, Jose Osmar Medina
Vanrenterghem, Yves
Vincenti, Flavio
Dong, Yuping
Thomas, Dolca
Larsen, Christian P.

September 2011

Hop Bicetre, Dept Nephrol & Transplantat, Le Kremlin Bicetre, FranceUniv Hosp Bellvitge, Dept Nephro...

An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients

Grinyo, Josep
Charpentier, Bernard
Pestana, Jose Medina
Vanrenterghem, Yves
Vincenti, Flavio
Reyes-Acevedo, Rafael
Apanovitch, Anne Marie
Gujrathi, Sheila
Agarwal, Mamta
Thomas, Dolca
Larsen, Christian P.

December 2010

Background. Belatacept is associated with better renal function and an improved cardiovascular/metab...

Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy

Hardinger KL
Sunderl
D
Wiederrich JA

May 2016

Karen L Hardinger, Daniel Sunderland, Jennifer A Wiederrich Division of Pharmacy Practice and Admini...

Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)

Vanrenterghem, Yves
Bresnahan, Barbara
Campistol, Josep
Durrbach, Antoine
Grinyo, Josep
Neumayer, Hans-Hellmut
Lang, Philippe
Larsen, Christian P.
Mancilla-Urrea, Eduardo
Pestana, Jose Medina
Block, Alan
Duan, Tao
Glicklich, Alan
Gujrathi, Sheila
Vincenti, Flavio

May 2011

Background. Cardiovascular disease, the most common cause of death with a functioning graft among ki...

Beneficial Effect of Belatacept on Health-Related Quality of Life and Perceived Side Effects: Results From the BENEFIT and BENEFIT-EXT Trials.

Dobbels, Fabienne
Wong, S
Min, Y
Sam, J
Kalsekar, A

January 2014

BACKGROUND: Patient-reported outcomes are increasingly incorporated in drug evaluation trials. Wheth...

Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT

Florman, Sander
Vincenti, Flavio
Durrbach, Antoine
Abouljoud, Marwan S
Bresnahan, Barbara
Garcia, Valter D
Mulloy, Laura
Rice, Kim
Rostaing, Lionel
Zayas, Carlos
Calderon, Kellie
Meier-Kriesche, Ulf
Polinsky, Martin
Yang, Lingfeng
Medina Pestana, Jose
Larsen, Christian P

April 2018

Clinical outcomes are generally worse for black vs nonblack renal allograft recipients. In BENEFIT a...

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial

Grinyó, Josep M.
del Carmen Rial, Maria
Alberu, Josefina
Steinberg, Steven M.
Manfro, Roberto C.
Nainan, Georgy
Vincenti, Flavio
Jones-Burton, Charlotte
Kamar, Nassim

November 2016

BackgroundIn a phase 2 study, kidney transplant recipients of low immunologic risk who switched from...

Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)

Vincenti, Flavio
Grinyo, Josep M.
Charpentier, Bernard
Pestana, Jose Osmar Medina
Rostaing, Lionel
Vanrenterghem, Yves
Di Russo, Gregory B.
Garg, Pushkal
Lin, Chen-Sheng
Larsen, Christian

August 2009

Univ Calif San Francisco, Transplant Ctr, San Francisco, CA 94143 USAUniv Hosp Bellvitge, Div Nephro...

Outcomes as a Function of Donor Criteria from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT-EXT).

Florman, Sander
Durrbach, Antoine
Larsen, Christian
Pestana, Jose Osmar Medina
Vanrenterghem, Yves
Vincenti, Flavio
Block, Alan
Garg, Pushkal
Copley, J. Brian
Xing, Jun
Grinyo, Josep

April 2010

Mt Sinai Med Ctr, New York, NY USAEmory Univ, Atlanta, GA 30322 USAUnifesp, Hosp Rim & Hipertens, Sa...

A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)

Durrbach, A.
Pestana, Jose Osmar Medina
Pearson, T.
Vincenti, F.
Garcia, V. D.
Campistol, J.
del Carmen Rial, M.
Florman, S.
Block, A.
Di Russo, G.
Xing, J.
Garg, P.
Grinyo, J.

March 2010

Recipients of extended criteria donor (ECD) kidneys are at increased risk for graft dysfunction/loss...

Long-Term Outcomes in Belatacept-Treated vs. Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results from BENEFIT-EXT, a Phase III Randomized Study

Durrbach, A
Pestana, J M
Florman, S
Del Carmen Rial, M
Rostaing, L
Kuypers, Dirk
Matas, A
Wekerle, T
Polinsky, M
Meier-Kriesche, H U
Munier, S
Grinyó, J

November 2016

In BENEFIT-EXT (NCT00114777), extended criteria donor kidney recipients were randomized to receive b...

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

Larsen, Christian P.
Grinyo, Josep
Medina-Pestana, Jose
Vanrenterghem, Yves
Vincenti, Flavio
Breshahan, Barbara
Campistol, Josep M.
Florman, Sander
del Carmen Rial, Maria
Kamar, Nassim
Block, Alan
Di Russo, Gregory
Lin, Chen-Sheng
Garg, Pushkal
Charpentier, Bernard

December 2010

Background. At 1 year, belatacept was associated with similar patient/graft survival, better renal f...

Belatacept and long-term outcomes in kidney transplantation

Vincenti, Flavio
Rostaing, Lionel
Grinyó Boira, Josep M.
Rice, Kim
Steinberg, Steven
Gaite, Luis
Moal, Marie-Christine
Mondragon-Ramírez, Guillermo A.
Kothari, Jatin
Polinsky, Martin S.
Meier-Kriesche, Herwig-Ulf
Munier, Stephane
Larsen, Christian P.

June 2021

Background: in previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosuppression, as...

G. Mondragon-Ramirezj, R. Reyes-Acevedok,

K. Ricel
L. Rostaingm
S. Steinbergn
J. Xingo
M. Agarwalo
M. B. Harlero
B. Charpentierp
Ehospital Dom Vicente Scherer–complexo Hospitalar
Khospital Miguel Hidalgo De Aguascalientes

October 2015

*Drs. Vincenti and Larsen contributed equally to the work described. The clinical profile of belatac...

and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2011.03914.x Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

J. O. Medina Pestanaa
J. M. Grinyob
Y. Vanrenterghemc
T. Beckerd
J. M. Campistole
S. Flormanf
V. D. Garciag
N. Kamarh
P. Langi
R. C. Manfroj
P. Massarik
M. D. C. Riall
M. A. Schnitzlerm
S. Vitkon
T. Duano
A. Blockp
M. B. Harlerp
A. Durrbachq
Medizinische Hochschule Hannover Hannover

October 2015

Recipients of extended-criteria donor (ECD) kid-neys have poorer long-term outcomes compared t

3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies

Charpentier, Bernard
Grinyo, Josep
Pestana, Jose Osmar Medina
Vanrenterghem, Yves
Vincenti, Flavio
Dong, Yuping
Thomas, Dolca
Larsen, Christian P.

September 2011

Hop Bicetre, Dept Nephrol & Transplantat, Le Kremlin Bicetre, FranceUniv Hosp Bellvitge, Dept Nephro...

An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients

Grinyo, Josep
Charpentier, Bernard
Pestana, Jose Medina
Vanrenterghem, Yves
Vincenti, Flavio
Reyes-Acevedo, Rafael
Apanovitch, Anne Marie
Gujrathi, Sheila
Agarwal, Mamta
Thomas, Dolca
Larsen, Christian P.

December 2010

Background. Belatacept is associated with better renal function and an improved cardiovascular/metab...

Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy

Hardinger KL
Sunderl
D
Wiederrich JA

May 2016

Karen L Hardinger, Daniel Sunderland, Jennifer A Wiederrich Division of Pharmacy Practice and Admini...

Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)

Vanrenterghem, Yves
Bresnahan, Barbara
Campistol, Josep
Durrbach, Antoine
Grinyo, Josep
Neumayer, Hans-Hellmut
Lang, Philippe
Larsen, Christian P.
Mancilla-Urrea, Eduardo
Pestana, Jose Medina
Block, Alan
Duan, Tao
Glicklich, Alan
Gujrathi, Sheila
Vincenti, Flavio

May 2011

Background. Cardiovascular disease, the most common cause of death with a functioning graft among ki...

Beneficial Effect of Belatacept on Health-Related Quality of Life and Perceived Side Effects: Results From the BENEFIT and BENEFIT-EXT Trials.

Dobbels, Fabienne
Wong, S
Min, Y
Sam, J
Kalsekar, A

January 2014

BACKGROUND: Patient-reported outcomes are increasingly incorporated in drug evaluation trials. Wheth...

Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT

Florman, Sander
Vincenti, Flavio
Durrbach, Antoine
Abouljoud, Marwan S
Bresnahan, Barbara
Garcia, Valter D
Mulloy, Laura
Rice, Kim
Rostaing, Lionel
Zayas, Carlos
Calderon, Kellie
Meier-Kriesche, Ulf
Polinsky, Martin
Yang, Lingfeng
Medina Pestana, Jose
Larsen, Christian P

April 2018

Clinical outcomes are generally worse for black vs nonblack renal allograft recipients. In BENEFIT a...

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial

Grinyó, Josep M.
del Carmen Rial, Maria
Alberu, Josefina
Steinberg, Steven M.
Manfro, Roberto C.
Nainan, Georgy
Vincenti, Flavio
Jones-Burton, Charlotte
Kamar, Nassim

November 2016

BackgroundIn a phase 2 study, kidney transplant recipients of low immunologic risk who switched from...

Primary Outcomes from a Randomized, Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)

Abstract

Extracted data

Primary Outcomes from a Randomized, Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)

Abstract

Extracted data

Related items

Related items